spacer
 
|
 


OVERVIEW
As retina fellows and ophthalmology residents near the end of their training, they may have questions and concerns about patient care and career choices. For example, while the availability of antivascular endothelial growth factor (anti-VEGF) treatments and corticosteroid delivery systems are providing a new standard of care for patients with age-related macular edema (AMD), new data are emerging and many questions remain, including:
  1. What are the roles of various diagnostic tests in patients with AMD?
  2. What is the best regimen for treating patients with AMD?
  3. How do I know when to switch treatments or stop treating?

This online, video-based roundtable discussion among faculty and 2 second-year retina fellows explores these questions and will provide participants with the opportunity to consider new data regarding available therapies as they create optimal treatment plans for patients. It will also provide guidance as they begin their new careers in the retina specialty.

GOAL
The goals of this activity are to provide retina fellows, ophthalmology residents, and practicing ophthalmologists with the most up-to-date clinical knowledge and strategies for the optimal treatment of patients with AMD and to address common concerns about career choices in the subspecialty of retina.

TARGET AUDIENCE
This activity is designed for retina fellows and ophthalmology residents as well as retina specialists and comprehensive ophthalmologists who treat patients with diseases of the retina. No prerequisites required.

LEARNING OBJECTIVES
After completing this activity, the participant should be able to demonstrate the ability to:
  • Describe various principles of retina practice management.
  • Evaluate the latest clinical data for the treatment of neovascular AMD.
  • Compare the effect of dosing strategies on the efficacy and safety of current and emerging therapies for the management of neovascular AMD.

The estimated time to complete this activity: 30 minutes

Release date: May 12, 2016.     Expiration date: May 12, 2017.

FEE INFORMATION
There is no fee for this educational activity.

PARTICIPATING FACULTY
Quan Dong Nguyen, MD, MSc (Course Director)
Professor and McGaw Endowed Chair in Ophthalmology
Inaugural Director and Chairman Emeritus, Stanley M. Truhlsen Eye Institute
Assistant Dean, Translational Research
University of Nebraska Medical Center
Omaha, Nebraska

Diana V. Do, MD (Co-Chair)
Professor of Ophthalmology
Vice Chair for Education
Director of the Carl Camras Center for Innovative Clinical Research
Director of the Ophthalmology Residency Training Program
Stanley M. Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, Nebraska

Jeffrey S. Heier, MD (Co-Chair)
Director, Vitreoretinal Service
Ophthalmic Consultants of Boston
Boston, Massachusetts

Paula Pecen, MD
Vitreoretinal Surgery Fellow
Cleveland Clinic, Cole Eye Institute
Cleveland, Ohio

William Rhoades, MD
Stanley M. Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, Nebraska

ACCREDITATION STATEMENT
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

JOINT PROVIDERSHIP STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and ASiM.

DISCLAIMER
The University of Nebraska Medical Center, Center for Continuing Education, presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The University of Nebraska Medical Center, Center for Continuing Education assumes no liability for the information herein.

DISCLOSURES
It is the policy of The University of Nebraska Medical Center, Center for Continuing Education to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a faculty or staff member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.

FACULTY AND STAFF DISCLOSURES
Quan Dong Nguyen, MD, MSc – Advisory Board/Consultant: AbbVie Inc., Allergan Inc, Astellas, Bayer, Bausch & Lomb Incorporated, Boehringer, Genentech Inc, Novartis, Ora Clinical, Regeneron Pharmaceuticals Inc, Santen Pharmaceuticals Co Ltd. Data Safety Monitoring Board: Acucela.

Diana V. Do, MD – Advisory Board/Consultant: Allergan Inc, Genentech Inc, Regeneron Pharmaceuticals Inc.

Jeffrey S. Heier, MD – Grants/research support for Acucela Inc, EyeGate, Genentech Inc, Kala Pharmaceuticals Inc, Kato Pharmaceuticals, Novartis, Ohr Pharmaceutical, QLT Inc, Stealth BioTherapeutics Inc, and ThromboGenics NV, Alcon Inc, Astellas Pharma US, Corcept Therapeutics Incorporated, Ophthotech Corporation, and Regeneron Pharmaceuticals Inc; Advisor/consultant for Acucela Inc, EyeGate, Genentech Inc, Kala Pharmaceuticals Inc, Kato Pharmaceuticals, Novartis, Ohr Pharmaceutical, QLT Inc, Stealth BioTherapeutics Inc, and ThromboGenics NV, Aerpio Therapeutics, Allergan Inc, Avalanche, Bayer, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Dutch Ophthalmic, Endo Optiks, Envisla, Foresight Biotherapeutics Inc, ForSight VISION4 Inc, Heidelberg Engineering Inc, Icon Therapeutics, Janssen Research & Development, Lpath Inc, Nano Retina, Optovue Inc, Quantel, Regeneron Pharmaceuticals Inc, RestorGenex, RetroSense Therapeutics, Santen Pharmaceutical Co Ltd, SciFluor Life Sciences LLC, Shire, Taiho Pharmaceutical Co LTD, Valeant Pharmaceuticals International Inc, Vision Medicines Inc, Xcovery, and XOMA.

Dr Pecen and Dr Rhoades, the planners, or other members at the University of Nebraska Medical Center, Center for Continuing Education and ASiM, who control content have no relevant financial relationships to disclose.

OFF-LABEL PRODUCT DISCUSSION
The following faculty members have disclosed that their presentation will reference unlabeled/unapproved use of drugs or products:

Dr Heier – Medications commonly used in the treatment of patients with retinal disease, and investigational medications currently in clinical development for the treatment of patients with retinal diseases will be discussed. The off-label or investigational status will be disclosed.

PRIVACY POLICY
For the University of Nebraska Medical Center, Center for Continuing Education privacy policy, please click here.

SYSTEM REQUIREMENTS
In order to ensure optimal viewing, please make sure your computer/device meets the following system requirements:
Processor (CPU): Intel Core i3 processor or greater; Windows 98/NT/200/XP or Mac OS 9/X or later, WebGL/HTML5 compatible browser such as Firefox, Chrome, or Safari; Windows Media Player 9.0 or later Flash player; 4 GB of RAM, DirectX9c video card with 512 MB RAM. Monitor settings: High color at 800 x 600 pixels, sound card and speakers, Adobe Acrobat Reader.

Please contact us with any technical questions or issues.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
  • Review the activity objectives and CME/CE information.
  • Review the enduring material.
  • Successfully complete the post-test (75% accuracy).
  • Click on the link provided at the end of the activity and complete the online evaluation instrument, including the attestation of hours attended.
  • Print your certificate online.

TABLE OF CONTENTS
Pre-Assessment

What You Need to Know Before Starting Your Practice:
   Top Ten List for AMD

Quan Dong Nguyen, MD, MSc; Diana V. Do, MD; Jeffrey S. Heier, MD; Paula Pecen, MD; and William Rhoades, MD

Post-Assessment

Submit a case to review at meeting:


procced to pretest


spacer  
  spacer
Advanced Studies in Medicine © 2014 Contact Us
spacer  
spacer